Pfizer Announces Phase III Non-Small Cell Lung Cancer Trial
Pfizer has begun a global Phase III trial of sunitinib malate in combination with erlotinib in previously treated patients with advanced non-small cell lung cancer.
The randomized, double-blind trial of 956 patients will compare the overall survival of patients taking sunitinib plus erlotinib with those taking erlotinib plus placebo.
Secondary endpoints of the study include progression-free survival, objective response rate, one-year survival, duration of response, adverse events and patient-reported outcomes.
Pfizer recently presented preliminary results from lead-in safety group in Phase II trials. In the trial, adverse events from 12 patients were mild-to-moderate, with the most frequent adverse events being diarrhea and fatigue.
Two patients had experienced a partial response and two patients experienced stable disease for more than 16 weeks, the company added.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct